Adhesion of multiple myeloma cells to the bone marrow microenvironment: implications for future therapeutic strategies.
Multiple myeloma is characterized by excess plasma cells within the bone marrow in association with monoclonal antibody protein in the serum and/or urine. Tumor cells localize within the marrow via an interaction of cell-surface adhesion molecules with their respective ligands on marrow stromal cells and extracellular matrix proteins. Stimulation of myeloma cells via these cell-surface molecules, either directly or via tumor cell adhesion to stromal cells, can induce autocrine or paracrine tumor cell growth mediated by interleukin 6. It might therefore be possible to develop innovative treatment strategies either to inhibit interleukin 6 production or to interrupt interleukin 6 signal transduction in multiple myeloma.
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA. kenneth_anderson@macmallgw.dfci.harvard.edu
M B
MB
Vidriales
K C
KC
Anderson
D000911:Antibodies, Monoclonal / Q000276:immunology; D001402:B-Lymphocytes / Q000378:metabolism*; D001853:Bone Marrow / Q000378:metabolism; D002448:Cell Adhesion / Q000502:physiology; D015815:Cell Adhesion Molecules / Q000378:metabolism; D002455:Cell Division; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics; D006133:Growth Substances / Q000494:pharmacology; D006801:Humans; D015850:Interleukin-6 / Q000494:pharmacology; D008954:Models, Biological; D009101:Multiple Myeloma / Q000378:metabolism* / Q000503:physiopathology / Q000628:therapy; D015398:Signal Transduction
D000911:Antibodies, Monoclonal; D015815:Cell Adhesion Molecules; D006133:Growth Substances; D015850:Interleukin-6